HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC Net Debt / EBITDA

The Net Debt to EBITDA of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 3.67. In the previous year, Net Debt to EBITDA was 1.23 — a change of 198.35% (higher).

Net Debt / EBITDA

3.67

YoY

198.35%

Last updated:

Net Debt to EBITDA of HaTay Pharmaceutical JSC is 2024 3.67 . Net Debt to EBITDA of HaTay Pharmaceutical JSC was 2023 1.23 . It decreases by 198.35% higher compared to the previous year.

The HaTay Pharmaceutical JSC Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
1.73 VND
Jan 1, 2018
1.63 VND
Jan 1, 2019
1.06 VND
Jan 1, 2020
1.27 VND
Jan 1, 2021
-1.84 VND
Jan 1, 2022
1.81 VND
Jan 1, 2023
1.23 VND
Jan 1, 2024
3.67 VND
The HaTay Pharmaceutical JSC Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
3.67+198.35%
1.23-31.96%
1.81-198.32%
-1.84-244.81%
1.27+19.44%
1.06-34.76%
1.63-5.83%
1.73-6.60%
1.85-30.24%
2.65+11.49%
2.38+49.00%
1.60-34.91%
2.45-12.71%
2.81-13.43%
3.25-24.38%
4.29+13.27%
3.79-29.47%
5.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Net Debt to EBITDA of HaTay Pharmaceutical JSC is 3.67 in 2024.

Net Debt to EBITDA of HaTay Pharmaceutical JSC changed from 1.23 to 3.67, representing a 198.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC